SPL

0.00%

9.7¢ starpharma holdings limited

Even a broken clock is right twice a day.... heard it over and...

First 10 Last

Share
Profile

Follow
mukesh2001

752 Posts.

20/03/17

21:48

Post #: 23494050
Share

Originally posted by antibotter ↑

Myownmoney

I believe, even though biotechcatalyst stated there is no obligation on Starpharma's part to announce completion of phase 3 trial, they will communicate it to ASX. Not only will it be in their best interests to do this, it would make no sense not to.

The fact that Starpharma stated twice in January, and once at end of February, expected completion of phase 3 trial reinforces for once - that the time line indicated will be met

In respect to Dep Docetaxel completion - your guess is as good as mine - and the fact that no time lines have been indicated - leads me to believe - earliest possible completion is before June quarter

Referring to license agreements signed for distribution and marketing of VivaGel BV formulation - Starpharma could be holding off (in my opinion) until completion of phase 3 trials and/or top line data. Why would they do this. Your guess is as good as mine. Lets wait and see what happens.

In the matter of capital raisings - it could be touch and go depending on timing of payments from Astrazeneca for milestone targets reached, upfront lump sum amount by agent in regards to development costs of VivaGel for BV. I anticipate June quarter to be a deadline for the cash. If not a capital raising could definitely be on the cards.

As several of the forum have alluded to - there are going to be several catalysts going forward (I for one, anticipate a few this month), that will not only propel share price higher, but start it to get noticed by others that have ignored Starpharma in the past.

I repeat what a regular poster stated on this site (sorry cannot remember who), it is not a matter of if........ but when.....

I noticed out of the 800,000 volume last Friday, only 11,500 were shorts.

Expand

Even a broken clock is right twice a day.... heard it over and over again... this month.. this qtr... this year... why bother ??? P&P&P

SPL Price at posting: 66.0¢ Sentiment: Sell Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BUX

Buxton projects new graphite province discovery at WA Narryer play

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

There are more pages in this discussion • 1 more message in this thread...

First 10 Last

Add SPL (ASX) to my watchlist

(20min delay)
Last 9.7¢		Change 0.000(0.00%)		Mkt cap ! $40.48M

Open	High	Low	Value	Volume
9.9¢	9.9¢	9.5¢	$35.24K	364.0K

Buyers (Bids)

No.	Vol.	Price($)
3	18326	9.5¢

Sellers (Offers)

Price($)	Vol.	No.
9.8¢	15262	2

View Market Depth

No.	Vol.	Price($)
2	8326	0.095
3	160000	0.094
2	134306	0.092
3	81442	0.090
1	30000	0.089

Price($)	Vol.	No.
0.098	5000	1
0.100	38876	3
0.105	199768	2
0.110	168286	9
0.115	85453	2

Last trade - 16.10pm 04/10/2024 (20 minute delay)

SPL (ASX) Chart

Even a broken clock is right twice a day.... heard it over and...

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Buxton projects new graphite province discovery at WA Narryer play

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BCI reaches close of funding facility for salt-first part of Mardie project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Even a broken clock is right twice a day.... heard it over and...

Top Stories

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Buxton projects new graphite province discovery at WA Narryer play

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BCI reaches close of funding facility for salt-first part of Mardie project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News